V Barbakadze
Tbilisi State Medical University, Georgia
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
A new series of linear and regular 3-arylglyceric acid-derived polyether, namely poly[oxy-1-carboxy-2-(3,4-dihydroxyphenyl) ethylene] or poly[3-(3,4-dihydroxyphenyl)glyceric acid] (PDPGA) was isolated and identified in the water-soluble, highmolecular weight fractions obtained from extracts of different species of comfrey and bugloss. According to data of 13C, 1H NMR, APT, 2D 1H/13C HSQC, 1D NOE and 2D DOSY experiments the polyoxyethylene chain is the backbone of the polymer molecule. 3,4-dihydroxyphenyl and carboxyl groups are regular substituents at two carbon atoms in the chain. The repeating unit of this regular polymer is 3-(3,4-dihydroxyphenyl)glyceric acid residue. Then basic monomeric moiety of this polymer, 3-(3,4-dihydroxyphenyl) glyceric acid (DPGA) was synthesized via Sharpless asymmetric dihydroxylation of trans-caffeic acid derivatives using an osmium catalyst. It is well known that epoxides are valuable synthons in organic synthesis and have been introduced into pharmaceutical applications, such as in the synthesis of antitumor drugs. Subsequently, the building block for the production of derivatives of PDPGA, methyl 3-(3,4-dimethoxyphenyl)glycidate was synthesized based on the Darzen reaction or by oxidation with oxone in order to produce in future derivatives of synthetic analogue of natural polymer through ring-opening polymerization of 2,3-disubstituted oxirane. PDPGA is endowed with intriguing pharmacological properties as anticomplementary, antioxidant, anti-inflammatory, burn and wound healing and anticancer properties. PDPGA and DPGA exerted anticancer activity in vitro and in vivo against human prostate cancer (PCA) cells. However, anticancer efficacy of PDPGA is more effective compared to its synthetic monomer. Overall, this study identifies PDPGA as a potent agent against PCA without any toxicity and supports its clinical application.
Email: v_barbakadze@hotmail.com
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report